# Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT07370909** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Longwood Biopharmaceuticals Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** LW402
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07370909
- **Lead sponsor:** Shanghai Longwood Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07370909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07370909, "Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07370909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*